Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD

ZuWallack, Richard; Mahler, Donald A.; Reilly, Donna; Church, Nina L.; Emmett, Amanda; Rickard, Kathleen; Knobil, Katharine

doi:10.1378/chest.119.6.1661

Cited by 211 publications

(141 citation statements)

References 48 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…more breathlessness) in patients with COPD over 1-2 yrs [151,152]. Numerous RCTs have also demonstrated improvements in TDI with pharmacotherapy compared with placebo in patients with COPD [150][151][152][153][154][155][156][157][158][159][160]. In an observational study [36], BDI/TDI were shown to be valid and responsive measures of acute changes in dyspnoea associated with a COPD exacerbation.…”

Section: Mrc Scalementioning

confidence: 99%

See 1 more Smart Citation

Outcomes for COPD pharmacological trials: from lung function to biomarkers

Cazzola¹,

MacNee²,

Martínez³

et al. 2008

Eur Respir J

751

566

View full text Add to dashboard Cite

The American Thoracic Society/European Respiratory Society jointly created a Task Force on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.

show abstract

Section: Mrc Scalementioning

confidence: 99%

“…In terms of feasibility, BDI/TDI have been used to measure dyspnoea with pharmacotherapy compared with placebo in numerous RCTs performed at multiple centres [152][153][154][155][156][157][158][159][160] In addition, self-administration led to increased responsiveness compared with interviewer administration [116,117].…”

Section: Mrc Scalementioning

confidence: 99%

Outcomes for COPD pharmacological trials: from lung function to biomarkers

Cazzola¹,

MacNee²,

Martínez³

et al. 2008

Eur Respir J

751

566

View full text Add to dashboard Cite

show abstract

“…Furthermore, there is a need to understand better what patients perceive as an 'exacerbation. ' Studies vary in their definitions of COPD 'exacerbations' [4][5][6][7][8][9][10][11][12][13][14][15], thus making evaluation and comparison difficult, a problem identified in the GOLD international guidelines for the management of COPD. Indeed, the authors of the GOLD guidelines use the term 'exacerbation' without a clear definition [16].…”

Section: Introductionmentioning

confidence: 99%

Exacerbations of chronic obstructive pulmonary disease — A patients' perspective

Adams

Chavannes

Jones

et al. 2006

Primary Care Respiratory Journal

View full text Add to dashboard Cite

SummaryBackground: Exacerbations are now an important clinical variable for research into, and management of, chronic obstructive pulmonary disease (COPD). Emphasis is usually on reductions in the incidence of exacerbations and their impact on quality of life. For such research to be useful and comparable there needs to be a clearly defined understanding of what is meant by the term 'exacerbation'. The aim of this study was to explore the notion of COPD exacerbations from the viewpoint of patients who had recently suffered an exacerbation. Methods: Using principles from grounded theory we conducted semi-structured, in-depth interviews with 23 volunteers from Denmark, the Netherlands and the UK who were identified as having had a COPD exacerbation. Interviews were recorded locally and translated into English for analysis. Notable themes were identified for each informant and their occurrences compared. Results: Patients' reasons for consulting fell into four categories: 'frightening change'; 'change in sputum colour'; 'gradual deterioration'; and 'opportunistic diagnosis'. Most patients consulted frequently about their COPD, but did not afford their exacerbations the same degree of prominence as healthcare professionals (HCPs). Conclusions: These data provide a new way of thinking about COPD exacerbations, offering a greater understanding and classification of the reasons underlying the decision of COPD patients to consult with HCPs. They suggest that the patient perspective of exacerbations is more complex than previously thought. These findings could be applied to clinical practice and research, facilitating focussed decisions on COPD management.

show abstract

“…Combination treatment with formoterol plus ipratropium provides better improvement of pulmonary function and a greater reduction in symptoms [103]; similarly, combination treatment with salmeterol plus theophylline provides significantly greater improvements in pulmonary function, significantly greater reductions in symptoms, dyspnoea, and albuterol use, and significantly fewer COPD exacerbations [104]. Taken together, these two studies suggest that combination therapy with long-acting bronchodilators with different mechanisms of action may, in fact, produce additive effects.…”

Section: Introductionmentioning

confidence: 91%